In a human clinical study involving 33 patients with sporadic ALS and 38 healthy control subjects, Sheean et al. recently showed that a systemic reduction in peripheral Tregs (including effector CD45RO+/FoxP3+ population) correlated with an enhanced rate of ALS progression. This evidence concerns the gene FOXP3 and amyotrophic lateral sclerosis.